Table 1.
Peptide pools of predicted CE, previously described TE or OLPs tested in immunoassays.
| Sourcea | Pool nameb | Typec | HLA-Id | Pool Size | Locatione | ||
|---|---|---|---|---|---|---|---|
|
| |||||||
| Restriction | Associated Prognosis | Sense | Antisense | ||||
|
| |||||||
| ARFs | B*27CE | CE | B*27 | Protective | 30 | 11 (37%) | 19 (63%) |
| B*57CE | CE | B*57 | Protective | 39 | 4 (10%) | 35 (90%) | |
| B*58CE | CE | B*58 | Protective | 90 | 10 (11%) | 80 (89%) | |
| B*5301/B*5501 | CE | B*5301 or B*5501 | Non-protective | 72 | 12 (17%) | 60 (83%) | |
|
| |||||||
| Gene | B*27 TE | TE | B*27 | Protective | 17 | 17 (100%) | |
| B*57/58 TE | TE | B*57 or B*58 | Protective | 32 | 32 (100%) | ||
| Gag | OLP | Multiple | Both | 123 | 123 (100%) | ||
| Pol-N | OLP | Multiple | Both | 125 | 125 (100%) | ||
| Pol-C | OLP | Multiple | Both | 124 | 124 (100%) | ||
a
ARF=alternative reading frame
b
CE= cryptic epitope, TE= traditional epitope, and Pol-N and Pol-C contain peptides representing the N or C terminal regions of the protein, respectively
c
OLP= overlapping peptides
d
alleles associated with disease progression in multiple prior studies
e
sense or forward and antisense or reverse alternate reading frames; number (%) of sense and antisense is based on pool size